EN DE
Watch Qurient Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Qurient Co. Ltd (115180) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Qurient Co. Ltd stock KRW 8,119, price KRW 15,790, that is 48.6% below the price, quality 26 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7115180002

QC Qurient Co. Ltd logo Thin data Nov 10, 2026

Qurient Co. Ltd

115180 · KQ
Very expensive, weak quality

Our calculation puts a fair price 49% below what the stock costs today.

Low debt
Fair value 8,119 KRW · Strongly overvalued
Quality 26/100
Weak Growth (revenue 3y −6.2 %/yr in KRW)
Negative free cash flow
Trails peers (1/8)
Narrow moat 7/100 · thin data
Thin data
Estimate
Watch Qurient Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

50,900 KRW 2,125 KRW Fair Value 8,119 KRW Jan 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 2,125 KRW – 50,900 KRW · fair‑value band 6,089 KRW – 10,149 KRW · the 15,790 KRW price screens above the 8,119 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Qurient Co. in your weekly email

Every Wednesday you see whether Qurient Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally.

Show moreShow less

The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors.

The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.

Stock analysis

Qurient Co. Ltd (115180) currently trades at 15,790 KRW, while our estimate is 8,119 KRW, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 6,089 KRW (bear) to 10,149 KRW (bull), the price of 15,790 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Qurient Co. Ltd reported revenue of 7.0B KRW in FY2025 versus 4.9B KRW in FY2021, a compound +9.3%/yr. Reported net income was −30.1B KRW in FY2025.

Key figures

Market cap 629B KRW (≈ $471M) Small · EPS (TTM) −974.01 KRW · Return on equity −102% · Return on assets (EBIT) −49.5% (5-year average) · Operating margin −673% · Revenue (TTM) 7.1B KRW · Revenue growth (YoY) +3.4% · Free cash flow −32.4B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 7 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −49%, 115180 screens richer than that median.

Fair Value

Bear 6,089 KRW Fair Value 8,119 KRW Bull 10,149 KRW
Price 15,790 KRW · Downside -48.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−23.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.2%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−496.2% (2021) → −426.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

115180 screens overvalued: fair value 49% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Qurient Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −48.6% · Bottom 25%
Profitability
Return on assets −48.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 3.4% · Above median
Balance sheet
Debt / equity 0.36× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 18.47× · Priciest 25%
P/S (12 months) 88.95× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)17 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)82 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 115180
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 115180
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 115180
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 115180
argenx SE ARGX $971.55 $908.40 −7% vs 115180
CSL Limited CSL A$201.68 A$181.40 −10% vs 115180
Moderna, Inc MRNA $250.83 $158.70 −37% vs 115180
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 115180
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 115180
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 115180

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Qurient Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Qurient Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/115180

Frequently asked questions

Is Qurient Co. Ltd (115180) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 8,119 KRW versus a price of 15,790 KRW, about 49% lower (overvalued).
What is the fair value of 115180?
Our estimate for Qurient Co. Ltd is 8,119 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 15,790 KRW.
What is the quality score of 115180?
Qurient Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qurient Co. Ltd (115180)?
Our calculated price target is the estimate of 8,119 KRW (as of Nov 10, 2026). Cautious scenario 6,089 KRW, optimistic scenario 10,149 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Qurient Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 8,119 KRW, about 49% lower versus a price of 15,790 KRW (overvalued). Cautious scenario 6,089 KRW, optimistic scenario 10,149 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Qurient Co. Ltd (115180)?
Qurient Co. Ltd reported trailing-twelve-month revenue of about 7.1B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Qurient Co. Ltd (115180)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qurient Co. Ltd it is 8,119 KRW per share (as of Nov 10, 2026), against a price of 15,790 KRW.
Is Qurient Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 115180 trades above its calculated fair value: price 15,790 KRW, fair value 8,119 KRW, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 115180?
No. The price is what the market pays today (15,790 KRW); the fair value is what the company's own numbers justify (8,119 KRW). For Qurient Co. Ltd the two are 7,671 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Qurient Co. Ltd worth?
The market values Qurient Co. Ltd at about 629B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 15,790 KRW; our models calculate a fair value of 8,119 KRW per share.
What do the bullish and bearish scenarios say about 115180?
Our models span a range for Qurient Co. Ltd: cautious scenario 6,089 KRW, base 8,119 KRW, optimistic 10,149 KRW per share (as of Nov 10, 2026, price 15,790 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Qurient Co. Ltd (115180)?
Balance-sheet figures for Qurient Co. Ltd (as of Nov 10, 2026): return on equity −102.0%, debt of 0.36 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 115180 from its 52-week high?
Qurient Co. Ltd trades at 15,790 KRW, about 69% below its 52-week high of 50,900 KRW and 7% above the low of 14,820 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 8,119 KRW is for.
Which stocks are comparable to Qurient Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qurient Co. Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 15,790 KRW, calculated fair value 8,119 KRW (−49%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Qurient Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qurient Co. Ltd (115180)?
The closing price on Nov 10, 2026 was 15,790 KRW. Our estimate is 8,119 KRW, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qurient Co. Ltd right now?
The price sits above even our optimistic bull case (10,149 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Qurient Co. Ltd

How large is the market capitalisation of Qurient Co. Ltd (115180)?
The market capitalisation of Qurient Co. Ltd is 629B KRW (≈ $471M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Qurient Co. Ltd (115180)?
Earnings per share at Qurient Co. Ltd are −974.01 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Qurient Co. Ltd (115180)?
The return on equity (ROE) of Qurient Co. Ltd is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qurient Co. Ltd (115180)?
On an EBIT basis the return on assets of Qurient Co. Ltd is −49.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qurient Co. Ltd (115180)?
The operating margin of Qurient Co. Ltd is −673% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qurient Co. Ltd (115180)?
Revenue at Qurient Co. Ltd is growing +3.4% versus a year earlier (3y avg −6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Qurient Co. Ltd (115180) generate?
The free cash flow of Qurient Co. Ltd is −32.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Qurient Co. Ltd in the live analysis

One click puts Qurient Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.